<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="to adulthood, there is no drug with exclusive indication for" exact="migraine" post="treatment in pediatric age. This raises several limitations in"/>
 <result pre="investigate the real evidence concerning the prophylactic therapy of pediatric" exact="migraine" post="by reviewing the clinical studies published between 2010 and"/>
 <result pre="by reviewing the clinical studies published between 2010 and 2019." exact="migraine" post="pediatric migraine prophylactic drugs therapy treatment guidelines preventive fig-count:"/>
 <result pre="the clinical studies published between 2010 and 2019. migraine pediatric" exact="migraine" post="prophylactic drugs therapy treatment guidelines preventive fig-count: table-count: equation-count:"/>
 <result pre="even in childhood and adolescence. The average prevalence of pediatric" exact="migraine" post="varies according to age, going from 3% in younger"/>
 <result pre="( 2). A noticeable social problem is represented by chronic" exact="migraine" post="(more than 15 days with headache a month) that"/>
 <result pre="although the last version (ICHD 3) considers some peculiarities of" exact="migraine" post="in pediatric age, such as the shorted duration of"/>
 <result pre="in terms of reduction of both frequency and intensity of" exact="migraine" post="attacks ( 6). Though representing a precious resource, the"/>
 <result pre="with placebo. Migraine prophylaxis aims at reducing the impact of" exact="migraine" post="by improving the frequency and intensity of attacks. In"/>
 <result pre="to investigate the actual evidence concerning prophylactic therapy of pediatric" exact="migraine" post="by reviewing clinical studies published between 2010 and 2019."/>
 <result pre="the above described strategy, 64 articles concerning preventive treatment of" exact="migraine" post="in children were included in our study. Among them,"/>
 <result pre="impotence, hallucinations, weight gain History of hypertension No history of" exact="asthma" post="or allergy No history of bradyarrhythmia TRICYCLIC ANTIDEPRESSANT Amitriptyline"/>
 <result pre="weight gain History of hypertension No history of asthma or" exact="allergy" post="No history of bradyarrhythmia TRICYCLIC ANTIDEPRESSANT Amitriptyline B 1"/>
 <result pre="gain Not obese patients history of depression or insomnia chronic" exact="migraine" post="ANTIEPILEPTIC DRUGS Sodium Valproate B 30 mg/kg/day Somnolence, nausea/vomiting,"/>
 <result pre="Male patients Topiramate A 2–3 mg/Kg/day Paresthesia, somnolence, dizziness, anorexia," exact="metabolic acidosis," post="cognitive/memory dysfunction Overweight No history of cognitive impairment SEROTONIN"/>
 <result pre="Increased appetite, weight gain, drowsiness, sleepiness, dizziness, dry mouth, tiredness," exact="constipation" post="No obese patients history of depression or insomnia Cyproheptadine"/>
 <result pre="Drowsiness, fatigue, increased appetite, weight gain, dizziness No history of" exact="asthma" post="NUTRACEUTICS Hydroxytryptophan C 100 mg Kg/day Nausea, bloating Flatulence,"/>
 <result pre="C 100 mg Kg/day Nausea, bloating Flatulence, loose stools or" exact="diarrhea" post="Mild intensity of the attack Low frequency Refusal of"/>
 <result pre="Coenzyme Q10 C 150–300 mg/day Nausea and/or vomiting upset stomach," exact="diarrhea" post="heartburn, loss of appetite, abdominal pain or discomfort Tenacetum"/>
 <result pre="properties on the cerebrovascular circulation. How flunarizine acts in preventing" exact="migraine" post="is not yet established but it probably has both"/>
 <result pre="the response rate was particularly high in patients with hemiplegic" exact="migraine" post="(85%). The study also showed that flunarizine was well-tolerated"/>
 <result pre="pediatric age are needed to confirm its effectiveness in pediatric" exact="migraine" post="( 13). Beta-Blockers Propranolol is a non-selective beta (b)"/>
 <result pre="receptors. Propranolol started to be used in the prophylaxis of" exact="migraine" post="for more than 50 years ( 14). Propranolol showed"/>
 <result pre="high profile of tolerability in several clinical trials on adult" exact="migraine" post="( 4). On the contrary, there are only a"/>
 <result pre="a dosage of 3 mg/kg/day) and valproate (30 mg/Kg/day) for" exact="migraine" post="prophylaxis in childhood. In this study, 60 patients were"/>
 <result pre="with non-pharmacologic treatments, showed efficacy in reducing the frequency of" exact="migraine" post="attacks in children (reduction of attack frequency &amp;gt;50% per"/>
 <result pre="of the most used drugs for preventive treatment of pediatric" exact="migraine" post="( 22). It is also recommended in cases of"/>
 <result pre="if combined with non-pharmacological measures, were both effective in reducing" exact="migraine" post="attacks frequency ( 19). Between July 2012 and November"/>
 <result pre="topiramate (50–100 mg/day) were evaluated for prophylactic therapy of pediatric" exact="migraine" post="in some controlled studies ( 7). In the last"/>
 <result pre="efficacy of valproate and propranolol for the preventive treatment of" exact="migraine" post="in the pediatric age. Sixty children (aged 5–15 years)"/>
 <result pre="in the pediatric age. Sixty children (aged 5–15 years) with" exact="migraine" post="without aura were included. Patients received propranolol (3 mg/kg/day)"/>
 <result pre="18). Topiramate is a first-line strategy for the treatment of" exact="migraine" post="in adults. In 2014, the U.S. Food and Drug"/>
 <result pre="the U.S. Food and Drug Administration (FDA) approved topiramate for" exact="migraine" post="treatment in the pediatric patients aged 12 to 17"/>
 <result pre="In adults, topiramate proved efficacious in the preventive treatment of" exact="migraine" post="with and without aura in episodic and chronic form,"/>
 <result pre="± 1.55 to 0.94 ± 0.35 h, respectively. The pediatric" exact="migraine" post="disability assessment score was reduced from 32.4 ± 9.3"/>
 <result pre="topiramate could be considered a safe and effective drug for" exact="migraine" post="therapy in pediatric patients ( 32). As reported above,"/>
 <result pre="migraine. Measures of secondary efficacy were the intensity of monthly" exact="migraine" post="and a response rate higher than 50%. During the"/>
 <result pre="p = 0.004; topiramate: 50%, p = 0.001). Also monthly" exact="migraine" post="intensity reduced in both groups ( p &amp;lt; 0.001)"/>
 <result pre="After 12 weeks of treatment, a significant reduction of monthly" exact="migraine" post="frequency was observed for both cinnarizine and topiramate ("/>
 <result pre="dose of 1–1.5 mg, administered for 6 months in 47" exact="migraine" post="subjects (7–14 years), was not more effective than placebo."/>
 <result pre="is drowsiness, weight gain and tenderness. Contraindications consist of asthma," exact="glaucoma" post="and peptic ulcer. Despite the lack of definitive data,"/>
 <result pre="weight gain and tenderness. Contraindications consist of asthma, glaucoma and" exact="peptic ulcer." post="Despite the lack of definitive data, Pizotifen is the"/>
 <result pre="rationale of the use of nutraceutics in the treatment of" exact="migraine" post="is based on the involvement of these substances in"/>
 <result pre="of coenzyme Q10 (100 mg/day) in the prophylaxis of pediatric" exact="migraine" post="( 44). A significant reduction in migraine frequency ("/>
 <result pre="prophylaxis of pediatric migraine ( 44). A significant reduction in" exact="migraine" post="frequency ( p &amp;lt; 0.001), severity ( p &amp;lt;"/>
 <result pre="present side effects of oral drugs or in drug resistant" exact="migraine" post="( 46). In a retrospective case series study, Ahmed"/>
 <result pre="dose of 75 units and maximum of 200) for chronic" exact="migraine" post="in a pediatric headache center from 2004 to 2010."/>
 <result pre="of pain ( 48). Complementary Therapies Non-pharmacological treatment for pediatric" exact="migraine" post="includes cognitive behavioral therapy, acupuncture, and biofeedback. As stated"/>
 <result pre="on 135 patients (mean age 14.4 ± 2) with chronic" exact="migraine" post="evaluated the efficacy at 20 weeks of the combined"/>
 <result pre="of acupuncture in reducing the frequency of the attacks of" exact="migraine" post="was shown in earlier studies ( 50, 51), no"/>
 <result pre="or pilot studies ( 53– 55). Overall, non-pharmacological treatment for" exact="migraine" post="can be a valid alternative for selected patients. The"/>
 <result pre="novelty of the last decade in the prophylaxis of pediatric" exact="migraine" post="comes from the results of the CHAMP study. This"/>
 <result pre="Placebo response rate is known to be high in pediatric" exact="migraine" post="studies ( 25). The high therapeutic efficacy of placebo"/>
 <result pre="not consider some dynamics that may influence the course of" exact="migraine" post="independently of drug therapy, such as psychological factors mostly"/>
 <result pre="no drug available in pediatric age with exclusive indication for" exact="migraine" post="treatment ( 59). From this point of view, there"/>
 <result pre="antagonists could be considered in postpubertal adolescent patients with frequent" exact="migraine" post="attacks (≥8 headache days/month), who have moderate to severe"/>
 <result pre="headache days/month), who have moderate to severe disability associated with" exact="migraine" post="(PedMIDAS score ≥30) and have failed ≥2 preventive therapies."/>
 <result pre="Bigal ME . Recent advances in the management of chronic" exact="migraine" post="in children. Expert Rev Neurother. ( 2018) 18: 231–"/>
 <result pre="Battan B et al. . Features of aura in paediatric" exact="migraine" post="diagnosed using the ICHD 3 beta criteria. Cephalalgia. ("/>
 <result pre="20349201 8. Abu-Arafeh I . Flunarizine for the prevention of" exact="migraine" post="- a new look at an old drug. Dev"/>
 <result pre="11 years' experience, with emphasis on its effect in hemiplegic" exact="migraine" post=". Dev Med Child Neurol. ( 2012) 54: 274–"/>
 <result pre="S Bayram E Sozmen K Yis U . The Paediatric" exact="migraine" post="disability assessment score is a useful tool for evaluating"/>
 <result pre="disability assessment score is a useful tool for evaluating prophylactic" exact="migraine" post="treatment . Acta Paediatr. ( 2014) 103: e484– 9."/>
 <result pre="4958813 15. Ludvigsson J . Propranolol used in prophylaxis of" exact="migraine" post="in children. Acta Neurol Scand. ( 1974) 50: 109–"/>
 <result pre="trial of propanolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients . Paediatr Drugs. ( 2010) 12:"/>
 <result pre="Y Haimi-Cohen Y Goldberg-Stern H Zeharia A Nonpharmacologic treatment of" exact="migraine" post="with low-dose propranolol or amitriptyline. Pediatr Neurol. ( 2012)"/>
 <result pre=". The efficacy and safety of topiramate for prophylaxis of" exact="migraine" post="in children. Iran J Child Neurol. ( 2013) 7:"/>
 <result pre="topiramate, and placebo in the prevention of childhood and adolescent" exact="migraine" post=". Headache. ( 2013) 53: 799– 816. 10.1111/head.12105 23594025"/>
 <result pre="clinical trial comparing the efficacy of melatonin and amitriptyline in" exact="migraine" post="prophylaxis of children . Iran J Child Neurol. ("/>
 <result pre="K et al. Treatment adherence to biobehavioral recommendations in pediatric" exact="migraine" post="as measured by electronic monitoring: the Adherence in Migraine"/>
 <result pre="et al. . Cognitive behavioral therapy plus amitriptyline for chronic" exact="migraine" post="in children and adolescents: a randomized clinical trial ."/>
 <result pre="behavioral therapy plus amitriptyline for children and adolescents with chronic" exact="migraine" post="reduces headache days to &amp;lt; 4 per month ."/>
 <result pre="637– 44. 10.1016/j.jpain.2017.01.002 28108386 29. collab: FDA approves Topamax for" exact="migraine" post="prevention in adolescents J Pain Palliat Care Pharmacother. ("/>
 <result pre=". The efficacy and safety of topiramate for prophylaxis of" exact="migraine" post="in children. Iran J Child Neurol. ( 2013) 7:"/>
 <result pre="35. Lawrence ER Hossain M Littlestone W . Sanomigran for" exact="migraine" post="prophylaxis; controlled multicenter trial in general practice. Headache. ("/>
 <result pre="3510125 37. Billie B Ludvigsson J Sanner G Prophylaxis of" exact="migraine" post="in children. Headache. ( 1977) 17: 61– 3. 10.1111/j.1526-4610.1977.hed1702061.x"/>
 <result pre="B Sartori S Battistella PA . The pharmacological treatment of" exact="migraine" post="in children and adolescents: an overview. Expert Rev Neurother."/>
 <result pre="M Pascotto A Carotenuto M . Nutraceutical preparations in childhood" exact="migraine" post="prophylaxis. Neurol Sci. ( 2012) 33: 1365– 8. 10.1007/s10072-012-1019-8"/>
 <result pre="of CoEnzyme Q10 in the prevention of pediatric and adolescent" exact="migraine" post=". Cephalalgia. ( 2011) 31: 897– 905. 10.1177/0333102411406755 21586650"/>
 <result pre="M . Ginkgolide B complex efficacy for brief prophylaxis of" exact="migraine" post="in schoolaged children: an open-label study . Neurol Sci."/>
 <result pre="Canetta E et al. . Circadian and seasonal variation of" exact="migraine" post="attacks in children. Headache. ( 2006) 46: 1571– 4."/>
 <result pre="al. . Efficacy and safety of erenumab (AMG334) in episodic" exact="migraine" post="patients with prior preventive treatment failure: a subgroup analysis"/>
</results>
